- Home
- MTRX vs ERAS Comparison
MTRX vs ERAS Comparison
Compare MTRX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- ERAS
- Stock Information
- Founded
- MTRX 1984
- ERAS 2018
- Country
- MTRX United States
- ERAS United States
- Employees
- MTRX N/A
- ERAS N/A
- Industry
- MTRX Engineering & Construction
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MTRX Consumer Discretionary
- ERAS Health Care
- Exchange
- MTRX Nasdaq
- ERAS Nasdaq
- Market Cap
- MTRX 327.8M
- ERAS 348.4M
- IPO Year
- MTRX 1990
- ERAS 2021
- Fundamental
- Price
- MTRX $14.00
- ERAS $1.44
- Analyst Decision
- MTRX Strong Buy
- ERAS Strong Buy
- Analyst Count
- MTRX 1
- ERAS 6
- Target Price
- MTRX $20.00
- ERAS $4.83
- AVG Volume (30 Days)
- MTRX 194.3K
- ERAS 1.3M
- Earning Date
- MTRX 05-07-2025
- ERAS 08-11-2025
- Dividend Yield
- MTRX N/A
- ERAS N/A
- EPS Growth
- MTRX N/A
- ERAS N/A
- EPS
- MTRX N/A
- ERAS N/A
- Revenue
- MTRX $742,408,000.00
- ERAS N/A
- Revenue This Year
- MTRX $9.98
- ERAS N/A
- Revenue Next Year
- MTRX $20.42
- ERAS N/A
- P/E Ratio
- MTRX N/A
- ERAS N/A
- Revenue Growth
- MTRX N/A
- ERAS N/A
- 52 Week Low
- MTRX $8.61
- ERAS $1.01
- 52 Week High
- MTRX $15.75
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MTRX 66.73
- ERAS 52.55
- Support Level
- MTRX $13.31
- ERAS $1.24
- Resistance Level
- MTRX $14.07
- ERAS $1.51
- Average True Range (ATR)
- MTRX 0.41
- ERAS 0.12
- MACD
- MTRX 0.10
- ERAS -0.00
- Stochastic Oscillator
- MTRX 89.40
- ERAS 57.89
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.